Sumitomo Group

Arqit and Sumitomo to make Japan Quantum Safe

Retrieved on:

Thursday, May 20, 2021

Mitsui, Companies, Economy of Japan, Sumitomo Group, Economic history of Japan, Keiretsu, Zaibatsu, Sumitomo Corporation

b'LONDON and NEW YORK, May 20, 2021 /PRNewswire/ -- Arqit Limited (Head Office: London SE1 2RE, United Kingdom; Founder and Chairman: DavidWilliams) (hereinafter, Arqit) and Sumitomo Corporation (Head Office: Chiyoda-ku, Tokyo;Representative Director, President and Chief Executive Officer: Masayuki Hyodo) (hereinafter,Sumitomo) today announce a long-term partnership to distribute Arqit\'s ground-breaking quantumencryptiontechnology for thebenefitoftheJapanese economy.\nSumitomo has signed a long-term distribution contract with Arqit and has secured the distributionrights to sell Arqit\'s technology to the Japanese government, enterprises and citizens.

Key Points:

b'LONDON and NEW YORK, May 20, 2021 /PRNewswire/ -- Arqit Limited (Head Office: London SE1 2RE, United Kingdom; Founder and Chairman: DavidWilliams) (hereinafter, Arqit) and Sumitomo Corporation (Head Office: Chiyoda-ku, Tokyo;Representative Director, President and Chief Executive Officer: Masayuki Hyodo) (hereinafter,Sumitomo) today announce a long-term partnership to distribute Arqit\'s ground-breaking quantumencryptiontechnology for thebenefitoftheJapanese economy.\nSumitomo has signed a long-term distribution contract with Arqit and has secured the distributionrights to sell Arqit\'s technology to the Japanese government, enterprises and citizens.
ItisasignificantimprovementnowonlegacyPKI encryptiontechnology, anddelivers protectionagainstquantum attack in future.The US Government department NIST published a White Paper in Aprilurging haste in the creation of new solutions to these problems Arqit and its partners have achievedjustsuchasolution.\nSumitomo expects to take a strong market lead in Japan in the exploitation of Arqit\'s technology toprotect the assets and information of the Japanese government, enterprises and citizens.The twoparties further intend to collaborate on new research and development to enhance Japaneseparticipationinthesupplychainandfor potentialjointbusinessoperation.
"\nArqit Founder and Chairman David Williams said: "The technology we have developed has thepotential to be of significance on a global basis.The world needs stronger, simpler cyber security andit is important that we make international partnerships with allied countries to protect each other\'sinterests.I am delighted to announce such a strong partnership with Sumitomo, which has been apioneering and creative partner during the development phase of Arqit\'s technology.We look forwardtomanyyearsofclose collaborationandmutual benefitin partnershipinJapan.
"\n'

Poxel Announces Notice of its Annual General Meeting to be Held on June 23, 2021

Retrieved on:

Wednesday, May 19, 2021

Health, Diabetes, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Sumitomo Group, Sumitomo Dainippon Pharma, Companies, Economy of Japan

In its mid-to-late-stage pipeline, the Company is currently advancing three drug candidates; several earlier-stage opportunities are also underway.

Key Points:

In its mid-to-late-stage pipeline, the Company is currently advancing three drug candidates; several earlier-stage opportunities are also underway.
Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.
Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.
Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

NEC X and Alchemist Accelerator Announce Partnership to Speed Successful Startup Launches

Retrieved on:

Friday, May 14, 2021

Companies, Business, Economy of Japan, Business incubators, Mitsui, NEC, Sumitomo Group, Startup company, Y Combinator

NEC X provides its Corporate Accelerator Program (CAP) together with AlchemistX, Alchemist\'s corporate innovation accelerator, to speed the development of early-stage startups.\n"Our CAP has evolved by leveraging the Silicon Valley startup ecosystem," said Shige Ihara, CEO of NEC X.

Key Points:

NEC X provides its Corporate Accelerator Program (CAP) together with AlchemistX, Alchemist\'s corporate innovation accelerator, to speed the development of early-stage startups.\n"Our CAP has evolved by leveraging the Silicon Valley startup ecosystem," said Shige Ihara, CEO of NEC X.
Additionally, NEC X CAP graduates have the option to join Alchemist for further growth and investment opportunity.
Alchemist has access to NEC X\'s early-stage startups using cutting-edge technologies from NEC R&D.\n"We are excited to partner with NEC X--we think the synergies are strong.
"\nAdditionally, NEC X and Alchemist are pleased to announce the graduation of new windowMetabob at the Alchemist 27th Demo Day today.

NEC X and Alchemist Accelerator Announce Partnership to Speed Successful Startup Launch

Retrieved on:

Thursday, May 13, 2021

Companies, Business, Economy of Japan, Business incubators, Mitsui, NEC, Sumitomo Group, Startup company

NEC X provides its Corporate Accelerator Program (CAP) together with AlchemistX, Alchemist\xe2\x80\x99s corporate innovation accelerator, to speed the development of early-stage startups.\n\xe2\x80\x9cOur CAP has evolved by leveraging the Silicon Valley startup ecosystem,\xe2\x80\x9d said Shige Ihara, CEO of NEC X.

Key Points:

NEC X provides its Corporate Accelerator Program (CAP) together with AlchemistX, Alchemist\xe2\x80\x99s corporate innovation accelerator, to speed the development of early-stage startups.\n\xe2\x80\x9cOur CAP has evolved by leveraging the Silicon Valley startup ecosystem,\xe2\x80\x9d said Shige Ihara, CEO of NEC X.
\xe2\x80\x9cFrom its establishment in 2018 to the present, NEC X has gone from being a new startup itself, to seeding 23 potential new ventures.
Additionally, NEC X CAP graduates have the option to join Alchemist for further growth and investment opportunity.
Alchemist has access to NEC X\xe2\x80\x99s early-stage startups using cutting-edge technologies from NEC R&D.\n\xe2\x80\x9cWe are excited to partner with NEC X\xe2\x80\x95we think the synergies are strong.

Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial

Retrieved on:

Thursday, May 13, 2021

Data management, Health, Technology, Software, Clinical trials, Pharmaceutical, Biotechnology, Sumitomo Dainippon Pharma, Sumitomo Group, Exscientia, Sumitomo Dainippon Pharma Co., Ltd., EXSCIENTIA, SUMITOMO DAINIPPON PHARMA CO., LTD.

Selective dual targeting is a major challenge for conventional drug discovery, and psychiatric indications also require exceptional selectivity to avoid off-target effects.

Key Points:

Selective dual targeting is a major challenge for conventional drug discovery, and psychiatric indications also require exceptional selectivity to avoid off-target effects.
To have what we believe to be the world\xe2\x80\x99s first three clinical molecules created using AI arising from our own platform \xe2\x80\x93 two with Sumitomo Dainippon Pharma - is a wonderful achievement.
Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created.
Exscientia\xe2\x80\x99s AI platform has now designed two drugs that are in Phase 1 human clinical trials.\nDrug design is precision engineering at the molecular scale.

Poxel Announces its Participation at the 64th Annual Meeting of the Japan Diabetes Society

Retrieved on:

Tuesday, May 11, 2021

Science, Other Science, Biotechnology, Research, Health, Diabetes, Clinical trials, Other Health, Sumitomo Group, Sumitomo Dainippon Pharma, Companies, Economy of Japan

In its mid-to-late-stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities.

Key Points:

In its mid-to-late-stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities.
Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.
Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.
Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Sharp NEC Display Solutions Debuts NC2443ML RB Laser Projector in Digital Cinema Projection Series

Retrieved on:

Tuesday, May 11, 2021

b'Sharp NEC Display Solutions, a global leader in the projector and display market , today announced the availability of the NC2443ML RB Laser Projector in its digital cinema projection series.

Key Points:

b'Sharp NEC Display Solutions, a global leader in the projector and display market , today announced the availability of the NC2443ML RB Laser Projector in its digital cinema projection series.
The NC2443ML is the ideal projection solution for theaters with medium to large-sized screens or projection booths that are looking for high-quality cinema projection.\nThe NC2443ML uses an RB laser light source to produce a rich color spectrum with unsurpassed brightness.
\xe2\x80\x9cThe NC2443ML projector is also extremely versatile and can display diverse content for medium-large sized auditoriums due to its modular light source at 24,000 lumens.
This projector also boasts increased flexibility, as it can be installed on the floor or the ceiling without the need for an exhaust system and features a wide variety of lens options.\nFor more information on Sharp NEC Display Solutions, visit https://www.sharpnecdisplays.us/ .\n*The lifetime may vary depending upon environmental conditions and does not constitute the warranty period.\nAbout Sharp NEC Display Solutions of America, Inc.\nSharp NEC Display Solutions of America, Inc. is the leading global provider of professional and commercial visual technology and digital signage solutions, wholly owned by Sharp NEC Display Solutions, Ltd .

Seanergy Announces Delivery of Capesize M/V Flagship

Retrieved on:

Tuesday, May 11, 2021

Keiretsu, Mitsui, Sumitomo Group, Zaibatsu, Capesize, Economy of Japan

b'GLYFADA, Greece, May 11, 2021 (GLOBE NEWSWIRE) -- Seanergy Maritime Holdings Corp. (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cSeanergy\xe2\x80\x9d) (NASDAQ: SHIP) announced today that it has taken delivery of the 176,387 dwt Capesize bulk carrier, built in 2013 by Mitsui Engineering & Shipbuilding Co., Ltd. in Japan, which was renamed M/V Flagship (the \xe2\x80\x9cVessel\xe2\x80\x9d).

Key Points:

b'GLYFADA, Greece, May 11, 2021 (GLOBE NEWSWIRE) -- Seanergy Maritime Holdings Corp. (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cSeanergy\xe2\x80\x9d) (NASDAQ: SHIP) announced today that it has taken delivery of the 176,387 dwt Capesize bulk carrier, built in 2013 by Mitsui Engineering & Shipbuilding Co., Ltd. in Japan, which was renamed M/V Flagship (the \xe2\x80\x9cVessel\xe2\x80\x9d).
The Vessel was subsequently financed through a leasing agreement with Cargill International SA (\xe2\x80\x9cCargill\xe2\x80\x9d or the \xe2\x80\x9cCharterer\xe2\x80\x9d).
The index-linked rate will be 102% of the BCI minus $1,325 per day.
Including this delivery, 84% percent of our fleet is employed under index-linked time charters.\nWe are also excited to further expand our strategic partnership with Cargill with another transaction, which is very beneficial commercially and environmentally.

Sharp NEC Display Solutions Announces First European Partner to One Global Partner Program

Retrieved on:

Thursday, May 6, 2021

b'Sharp NEC Display Solutions, a global leader in the projector and display market , has announced the first European partner to join the Sharp/NEC Global Partner Program.

Key Points:

b'Sharp NEC Display Solutions, a global leader in the projector and display market , has announced the first European partner to join the Sharp/NEC Global Partner Program.
As a Global Partner, Kinly will receive dedicated resources, including sales support from the Sharp/NEC Global Team, as well as access to its global technology portfolio and much more.\n\xe2\x80\x9cThe One Global Partner Program underscores Sharp/NEC\xe2\x80\x99s global service and support in the AV industry,\xe2\x80\x9d said Betsy Larson, Senior Vice President of Sales at Sharp NEC Display Solutions.
Sharp NEC Display Solutions provides technology for collaboration and meeting rooms, command and control, workspaces, and digital signage for a wide range of verticals including enterprise, corporate, education, retail, transportation, healthcare, and regional and federal government.\nFor more information on Sharp NEC Display Solutions, visit https://www.sharpnecdisplays.us .\nAbout Sharp NEC Display Solutions of America, Inc.\nSharp NEC Display Solutions of America, Inc. is the leading global provider of professional and commercial visual technology and digital signage solutions, wholly owned by Sharp NEC Display Solutions, Ltd .
Sharp NEC Display offers one of the broadest visual solutions portfolios in the industry, innovating in LCD displays, lamp and laser projectors, dvLED, 8K and 5G technology, collaboration solutions, calibration tools, IoT and AI driven analytics.

Investigation Report on China's Meropenem Market 2021-2025 - ResearchAndMarkets.com

Retrieved on:

Thursday, May 6, 2021

Health, Pharmaceutical, Countries, Health, Articles, Sumitomo Group, Meropenem, Pyrrolidines, Sumitomo Dainippon Pharma, Imperial Chemical Industries, COVID-19 pandemic, China

b'The "Investigation Report on China\'s Meropenem Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019.

Key Points:

b'The "Investigation Report on China\'s Meropenem Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019.
In 2020, sales revenue of Meropenem in China was CNY1.88 billion, which decreased 12.2% Year on Year.
The main reason is that the COVID-19 epidemic has impacted the hospitals\' overall operation.
Meropenem is jointly developed by Sumitomo Dainippon Pharma and Imperial Chemical Industries (ICI).